Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in alzheimer's disease and vascular dementia

Journal of Alzheimer's Disease

Volumn 34, Issue 3, 2013, Pages 673-679

  Olsson, Bob ^a   Hertze, Joakim ^e   Ohlsson, Mattias ^f   Nägga, Katarina ^e   Höglund, Kina ^b   Basun, Hans ^c   Annas, Peter ^b   Lannfelt, Lars ^c   Andreasen, Niels ^d   Minthon, Lennart ^e   Zetterberg, Henrik ^a,g   Blennow, Kaj ^a   Hansson, Oskar ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; biomarker; cerebrospinal fluid; dementia; HFABP; vascular dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; FATTY ACID BINDING PROTEIN; HEART FATTY ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NERVE CELL NECROSIS; NERVE DEGENERATION; NORMOTENSIVE HYDROCEPHALUS; OPEN STUDY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SEMANTIC DEMENTIA;

EID: 84876364097     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121384     Document Type: Article

References (31)

1. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, Montine TJ (2008) Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 7, 704-714. (Pubitemid 351965506)
2. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
3. Seshadri S,Wolf PA(2007) Lifetime risk of stroke and dementia: Current concepts, and estimates from the Framingham Study. Lancet Neurol 6, 1106-1114. (Pubitemid 350123607)
4. Wallin A, MilosV, Sjogren M, Pantoni L, Erkinjuntti T (2003) Classification and subtypes of vascular dementia. Int Psychogeriatr 15(Suppl 1), 27-37. (Pubitemid 37175164)
5. Richieri GV, Ogata RT, Kleinfeld AM (1999) The measurement of free fatty acid concentration with the fluorescent probe ADIFAB: A practical guide for the use of the ADIFAB probe. Mol Cell Biochem 192, 87-94. (Pubitemid 29171457)
6. Ockner RK, Manning JA, Poppenhausen RB, Ho WK (1972) A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science 177, 56-58.
7. Heuckeroth RO, Birkenmeier EH, Levin MS, Gordon JI (1987) Analysis of the tissue-specific expression, developmental regulation, and linkage relationships of a rodent gene encoding heart fatty acid binding protein. J Biol Chem 262, 9709-9717.
8. Glatz JF, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-Visser MP, Hermens WT (1998) Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta 272, 87-92. (Pubitemid 28179620)
9. Nakata T, Hashimoto A, Hase M, Tsuchihashi K, Shimamoto K (2003) Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 99, 96-104. (Pubitemid 36506388)
10. Cheon MS, Kim SH, Fountoulakis M, Lubec G (2003) Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 225-234. (Pubitemid 38339937)
11. Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K (2010) CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis 22, 1281- 1288.
12. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, OttoM(2007) Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: Marker candidates for dementia with Lewy bodies. Neurodegener Dis 4, 366-375. (Pubitemid 47134683)
13. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 370, 36-39. (Pubitemid 39369852)
14. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis 27, 665-676.
15. Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A (2011) Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement Geriatr Cogn Dis Extra 1, 31-42.
16. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer's disease: A clinical follow-up study of 4.7 years. J Alzheimers Dis 21, 1119-1128.
17. (1987) Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd Revision, American Psychiatric Publishing, Inc.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
19. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194. (Pubitemid 39222988)
20. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, HofmanAet al. (1993)Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
21. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW (2000) Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59, 23-30. (Pubitemid 30479402)
22. McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop: Diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 53, 902-905. (Pubitemid 29442100)
23. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N(2007) Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 419, 18-22. (Pubitemid 46694097)
24. (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition, American Psychiatric Publishing, Inc.
25. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K (2005) Simultaneous measurement of betaamyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51, 336-345. (Pubitemid 40175803)
26. Hosmer DW, Lemeshow S (1989) Applied Logistic Regression, John Wiley & Sons, Inc., New York.
27. Bishop CM (1995) Neural Networks for Pattern Recognition, Oxford University Press, Oxford.
28. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC (2003) A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 3, 1495-1499. (Pubitemid 37048075)
29. Shioda N, Yamamoto Y, Watanabe M, Binas B, Owada Y, Fukunaga K (2010) Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci 30, 3146-3155.
30. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553- 1562. (Pubitemid 40617691)
31. BlennowK, ZetterbergH, Rinne JO, Salloway S,Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69, 1002-1010.